Takeda Pharmaceutical Company Limited American Depositary Shares (each r (TAK) Covered Calls

You can sell covered calls on Takeda Pharmaceutical Company Limited American Depositary Shares (each r to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TAK (prices last updated Fri 4:16 PM ET):

Takeda Pharmaceutical Company Limited American Depositary Shares (each r (TAK) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
13.10 +0.09 13.02 13.50 1.8M - 0.0
Covered Calls For Takeda Pharmaceutical Company Limited American Depositary Shares (each r (TAK)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Jan 17 12.5 0.45 13.05 -4.2% -52.9%
Feb 21 12.5 0.00 13.50 -7.4% -42.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.